Propanc Biopharma
PPCB
Propanc Biopharma (PPCB) news
Recent news
Propanc Biopharma - to file Phase 1b clinical trial application for PRP in advanced cancer in Q4
Propanc Biopharma, Inc. (Nasdaq: PPCB) has announced plans to file a clinical trial application for its Phase 1b, First-In-Human (FIH) study of PRP, its lead asset, in the fourth quarter of 2026. The upcoming trial will evaluate PRP as a treatment for 30–40 advanced cancer patients with solid…
AInvest Wire · Aug 12, 2026Propanc Biopharma - to accelerate Phase 1b first-in-human study in pancreatic cancer
AInvest Wire · Aug 6, 2026Propanc Biopharma signs MOU with Avance Clinical Pty Ltd
AInvest Wire · Jul 7, 2026Propanc Biopharma initiates $5.0 million share repurchase program
AInvest Wire · Jul 2, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.